霍奇金淋巴瘤老年患者的整体存活率和死亡原因:挪威基于人口的病例控制研究
Kjersti Lia1, Rasmus R K Jørgensen2, Bente L Wold3
1Vestre Viken, Bærum Hospital, Department of Oncology, Gjettum, Norway; Faculty of Medicine, University of Oslo. kjerli@vestreviken.no.
Haematologica
|October 26, 2023
概括
老年霍奇金淋巴瘤患者在治疗意图治疗后的生存率有所改善. 然而,其他血液癌症的死亡风险仍然很高,而不是长期治疗并发症.
科学领域:
- 在瘤学瘤学.
- 流行病学 流行病学
- 老年病的医生 老年病的医生
背景情况:
- 老年霍奇金淋巴瘤 (HL) 患者的研究不足,并且经常被排除在临床试验之外.
- 在这个人口群体中,关于生存和死亡原因的基于人口的数据是有限的.
研究的目的:
- 通过竞争风险分析,研究老年HL患者的因果特异性生存率.
- 为了将老年HL患者的生存结果与普通人群进行比较.
主要方法:
- 国家基于人口的研究,使用来自挪威癌症登记处 (2000-2015年) 的数据.
- 包括被诊断患有HL的60岁以上的患者.
- 竞争风险分析将HL患者与挪威死亡原因登记处的无癌症对照进行比较.
主要成果:
- 在492名患者中,17%的患者不符合HL导向治疗的条件,15%的患者接受了息治疗,69%的患者接受了治愈治疗.
- 平均整体存活时间各不相同:0.5年 (不合格),0.8年 (缓解),9.1年 (治愈).
- 在治愈治疗的患者中,与对照组相比,从HL死亡的10年风险差异为28%,与治疗相关的死亡率为6.5%. 观察到死于其他血液性恶性瘤的风险增加,但不是由于长期治疗并发症.
结论:
- 治愈意图治疗为大多数符合条件的老年霍奇金淋巴瘤患者提供疾病控制.
- 与普通人群相比,老年HL患者面临着明显更高的HL和其他血液恶性瘤死亡风险.
- 生存结果强烈依赖于治疗资格和意图,突出显示了在这个年龄段需要量身定制的治疗策略.
相关概念视频
Cancer Survival Analysis
357
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
357
Comparing the Survival Analysis of Two or More Groups
201
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
201
Actuarial Approach
80
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
80
Kaplan-Meier Approach
154
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
154
Assumptions of Survival Analysis
136
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
136
Life Tables
111
A life table is a statistical tool that summarizes the mortality and survival patterns of a population, providing detailed insights into the likelihood of survival or death across different age intervals within a cohort. By organizing data on survival probabilities and mortality rates, life tables offer a clear snapshot of population dynamics over time. They are extensively used in demography, public health, actuarial science, and ecology to analyze life expectancy, design health interventions,...
111


